Irritable Bowel Syndrome Treatment Market Size, Share And Growth Analysis By Leading Players - Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals

Irritable bowel syndrome is a gastrointestinal tract disorder characterized by abdominal pain and altered bowel habits. It hampers the natural movement of intestinal muscle linings to move food along the digestive tract. Depending on the symptoms, the syndrome is distinguished as mild and severe irritable bowel syndrome. These symptoms include cramping, abdominal pain, bloating and gas, mucus in the stool, constipation, and diarrhea.

Exact cause of occurrence of irritable bowel syndrome is unknown though, it is associated with increased awareness of bodily functions, and abnormal gastrointestinal tract movements. Diagnosis of irritable bowel syndrome is done by tests such as blood tests, stool tests, endoscopic procedures and external imaging procedures. Patients suffering from irritable bowel syndrome may experience complications namely, deep ulcerations, infections, and malnutrition and bowel obstructions. Treatment of irritable bowel syndrome involves relieving the patient from the symptoms and improving the quality of life.

Request For A Sample Copy Of This Exclusive Report: https://www.coherentmarketinsights.com/insight/request-sample/506

Robust pipeline with symptom specific indications and subsequent launches in the forecast period is expected to boost the market
According to International Foundation for Functional Gastrointestinal Disorders, 2016, worldwide prevalence of irritable bowel syndrome is around 10-15%. Furthermore, there are between 2.4 and 3.5 million annual physician visits for IBS in the U.S. according to the same source. According to the Anxiety and Depression Association of America, approximately one in five adults in the U.S. is suffering with irritable bowel syndrome. Irritable bowel syndrome shows a wide range of symptoms, so, the treatment is decided on predominance of the symptoms such as, in pain predominant patients, antispasmodic agents or tricyclic antidepressants are used.

The prevalence of irritable bowel syndrome is predominant in female than in males. According to the International Foundation for Functional Gastrointestinal Disorders, 2 in 3 IBS sufferers are female. Some of the U.S. Food & Drug Administration approved drugs for relieving the symptoms associated with IBS are Lotronex (Alosetron), Amitiza (Lubiprostone), Linzess (Linclotide), and Xifaxan (Rifaximin).

Increase in levels of stress and adoption of sedentary lifestyle is expected to increase the prevalence of lifestyle disorders namely irritable bowel syndrome

The number of available irritable bowel syndrome drugs has increased over the last few years and new drugs have been approved for the treatment. North America accounts for the largest share in the global irritable bowel syndrome treatment market, followed by Europe and Asia-pacific, respectively. According to an article published in the Brandon Gaille in 2017, on an average, junk food accounts for 28.8% of the total caloric intake of an American.

Some major players operating in the irritable bowel syndrome treatment market are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.

Download the PDF brochure:
www.coherentmarketinsights.com/insight/request-pdf/506

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.